A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Neuroblastoma
DRUG: LY3295668 Erbumine|DRUG: Topotecan|DRUG: Cyclophosphamide
Number of Participants with Dose Limiting Toxicities (DLTs), Number of Participants with DLTs, Baseline through Cycle 2 (28 Day Cycle)|Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR), ORR, Baseline through Measured Progressive Disease (Estimated up to 5 Years)|Duration of Response (DoR), DoR, Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 5 Years)
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668, PK: AUC of LY3295668, Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)|PK: AUC of LY3295668 in Combination with Topotecan and Cyclophosphamide, PK: AUC of LY3295668 in Combination with topotecan and cyclophosphamide, Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)|Best Overall Response (BOR): Percentage of Participants with CR, PR, Stable Disease (SD), or Progressive Disease (PD), BOR, Baseline to Date of Objective Disease Progression (Estimated up to 5 Years)|Progression-Free Survival (PFS), PFS, Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 5 Years)|Overall Survival (OS), OS, Baseline to Date of Death from Any Cause (Estimated up to 6 Years)
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.